Cwm LLC Has $1.87 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Cwm LLC decreased its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 13.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,793 shares of the company’s stock after selling 3,127 shares during the quarter. Cwm LLC’s holdings in Axsome Therapeutics were worth $1,869,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in AXSM. Vanguard Group Inc. raised its stake in Axsome Therapeutics by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 3,740,278 shares of the company’s stock worth $298,474,000 after purchasing an additional 43,512 shares in the last quarter. Bellevue Group AG raised its position in shares of Axsome Therapeutics by 7.9% in the first quarter. Bellevue Group AG now owns 685,476 shares of the company’s stock valued at $54,701,000 after buying an additional 50,104 shares in the last quarter. XTX Topco Ltd boosted its stake in shares of Axsome Therapeutics by 177.9% in the second quarter. XTX Topco Ltd now owns 11,205 shares of the company’s stock valued at $902,000 after buying an additional 7,173 shares during the period. Tri Locum Partners LP grew its position in Axsome Therapeutics by 198.4% during the second quarter. Tri Locum Partners LP now owns 306,513 shares of the company’s stock worth $24,674,000 after buying an additional 203,802 shares in the last quarter. Finally, Blair William & Co. IL grew its position in Axsome Therapeutics by 645.9% during the first quarter. Blair William & Co. IL now owns 63,547 shares of the company’s stock worth $5,071,000 after buying an additional 55,027 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Insider Activity

In related news, Director Mark E. Saad sold 11,016 shares of the stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total value of $1,005,870.96. Following the completion of the sale, the director now directly owns 10,002 shares in the company, valued at $913,282.62. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, COO Mark L. Jacobson sold 47,739 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $84.26, for a total value of $4,022,488.14. Following the sale, the chief operating officer now directly owns 5,783 shares of the company’s stock, valued at approximately $487,275.58. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Mark E. Saad sold 11,016 shares of the stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the sale, the director now owns 10,002 shares of the company’s stock, valued at approximately $913,282.62. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 22.40% of the company’s stock.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $86.43 on Wednesday. The stock has a 50-day moving average price of $89.03 and a two-hundred day moving average price of $81.18. Axsome Therapeutics, Inc. has a 12 month low of $55.02 and a 12 month high of $98.40. The company has a market capitalization of $4.11 billion, a PE ratio of -13.55 and a beta of 1.26. The company has a current ratio of 2.48, a quick ratio of 2.40 and a debt-to-equity ratio of 1.77.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, August 5th. The company reported ($1.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.06. Axsome Therapeutics had a negative net margin of 105.85% and a negative return on equity of 117.46%. The business had revenue of $87.17 million during the quarter, compared to analyst estimates of $84.53 million. Analysts expect that Axsome Therapeutics, Inc. will post -4.73 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 1st. Needham & Company LLC reiterated a “buy” rating and set a $130.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, September 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $107.00 target price on shares of Axsome Therapeutics in a research report on Monday, September 16th. Royal Bank of Canada increased their price target on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Finally, Bank of America raised shares of Axsome Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $95.00 to $106.00 in a research note on Tuesday, August 6th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $124.64.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.